Mixed Dyslipidemia - Pipeline Review, H1 2016

  • ID: 3766783
  • Report
  • 69 pages
  • Global Markets Direct
1 of 5
Mixed Dyslipidemia - Pipeline Review, H1 2016

Summary

The report ‘Mixed Dyslipidemia - Pipeline Review, H1 2016’, provides an overview of the Mixed Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
- The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Mixed Dyslipidemia Overview

Therapeutics Development

Pipeline Products for Mixed Dyslipidemia - Overview

Mixed Dyslipidemia - Therapeutics under Development by Companies

Mixed Dyslipidemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Mixed Dyslipidemia - Products under Development by Companies

Mixed Dyslipidemia - Companies Involved in Therapeutics Development

Amgen Inc.

CymaBay Therapeutics, Inc.

Hanmi Pharmaceuticals, Co. Ltd.

Matinas BioPharma Holdings, Inc.

Pfizer Inc.

Thetis Pharmaceuticals LLC

Mixed Dyslipidemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

bococizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

evolocumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HCP-1105 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IONIS-ANGPTL3LRx - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MAT-9001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MBX-8025 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TP-452 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Mixed Dyslipidemia - Recent Pipeline Updates

Mixed Dyslipidemia - Dormant Projects

Mixed Dyslipidemia - Discontinued Products

Mixed Dyslipidemia - Product Development Milestones

Featured News & Press Releases

May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting

Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab)

Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder

Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins

Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol

Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Mixed Dyslipidemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016

Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016

Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016

Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016

Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016

Mixed Dyslipidemia - Dormant Projects, H1 2016

Mixed Dyslipidemia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Mixed Dyslipidemia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Amgen Inc.
CymaBay Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Matinas BioPharma Holdings, Inc.
Pfizer Inc.
Thetis Pharmaceuticals LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll